Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antibodies to infliximab influence outcomes and drug levels in IBD

January's issue of the American Journal of Gastroenterology reviews the impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with IBD.

News image

Antibodies to infliximab have been associated with loss of clinical response and lower serum infliximab levels in some studies of patients with inflammatory bowel disease (IBD).

This has important implications for patient management and development of novel biologic therapies.

Dr Kavinderjit Nanda from Massachusetts, USA performed a systematic review and meta-analysis of studies that reported clinical outcomes and infliximab levels according to patients’ Antibodies to infliximab status.

MEDLINE, Web of Science, CINAHL, Scopus, and EMBASE were searched for eligible studies.

The researchers reported quality assessment was undertaken using GRADE criteria.

Raw data from studies meeting inclusion criteria was pooled for meta-analysis of effect estimates.

Sensitivity analysis was performed for all outcomes.

The team of doctors reported that a funnel plot was performed to assess for publication bias.

The team identified 13 studies that met the inclusion criteria, and reported results in 1,378 patients with inflammatory bowel disease.

All included studies had a high risk of bias in at least 1 quality domain.

The team of researchers found that the pooled risk ratio of loss of clinical response to infliximab in patients with IBD who had antibodies to infliximab was 3.2, when compared with patients without antibodies to infliximab.

This effect estimate was predominantly based on data from patients with Crohn's disease.

The doctors found that data only from patients with ulcerative colitis exhibited a non-significant relative risk of loss of response of 2.2 in those with antibodies to infliximab.

The standardized mean difference in trough serum infliximab levels between groups was −0.8
American Journal of Gastroenterology

Heterogeneity existed between studies, in both methods of antibodies to infliximab detection, and clinical outcomes reported.

The team observed that 3 studies reported trough serum infliximab levels according to antibodies to infliximab status.

The standardized mean difference in trough serum infliximab levels between groups was −0.8.

A funnel plot suggested the presence of publication bias.

Dr Nanda's team concludes, "The presence of antibodies to infliximab is associated with a significantly higher risk of loss of clinical response to infliximab and lower serum infliximab levels in patients with inflammatory bowel disease."

"Published studies on this topic lack uniform reporting of outcomes."

"High risk of bias was present in all the included studies."

Am J Gastroenterol 2013; 108:40–47
15 January 2013

Go to top of page Email this page Email this page to a colleague

 30 January 2015

Advanced search
 30 January 2015 
HIV-associated NAFLD and primary NAFLD
 30 January 2015 
Narcotic use in children with IBD
 30 January 2015 
Removal of rectal neoplasms
 29 January 2015 
Pyloric compliance in gastroparesis
 29 January 2015 
Gastric cancer in peptic ulcer disease
 29 January 2015 
Genetics and risk of Barrett's
 28 January 2015 
Metabolic syndrome in celiac disease
 28 January 2015 
Remission in Crohn's disease
 28 January 2015 
Surgery and quality of life in rectal cancer
 27 January 2015 
Outcomes for liver transplantation
 27 January 2015 
Psychological distress and fecal composition in IBS
 27 January 2015 
Risk of upper GI cancers in GERD
 26 January 2015 
Breath analysis for IBD
 26 January 2015 
Fecal microbiota transplantation
 26 January 2015 
Antidepressants and GERD
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 23 January 2015 
Fecal microbiota transplantation
 22 January 2015 
NASH and lipid improvements
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Novel techniques for Barrett's screening
 20 January 2015 
Food intolerance
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 16 January 2015 
Fecal incontinence
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us